Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
Abstract Rivaroxaban (RIV; Xarelto; Janssen Pharmaceuticals, Beerse, Belgium) is one of the direct oral anticoagulants. The drug is a strong substrate of cytochrome P450 (CYP) enzymes and efflux transporters. This study aimed to develop a physiologically‐based pharmacokinetic (PBPK) model for RIV. I...
Main Authors: | Lien Thi Ngo, Sung‐yoon Yang, Sooyoung Shin, Duc Tuan Cao, Hung Van Nguyen, Sangkeun Jung, Jae‐Young Lee, Jong‐Hwa Lee, Hwi‐yeol Yun, Jung‐woo Chae |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-11-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12844 |
Similar Items
-
Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01) -
Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans
by: Lien Thi Ngo, et al.
Published: (2023-05-01) -
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
by: Lien Thi Ngo, et al.
Published: (2023-01-01) -
Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Minsoo Kim, et al.
Published: (2019-03-01) -
NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers
by: Gonzalo Villapalos-García, et al.
Published: (2023-09-01)